MG
NBIX icon

Mather Group’s Neurocrine Biosciences NBIX Stock Holding History

Mather Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.6K Hold
158
– – ﹤0.01% 1266
2026
Q1 		$20.8K Buy
+158
New +$21K ﹤0.01% 1267
2025
Q4 		– Sell
-168
Closed -$23.6K – 1288
2025
Q3 		$23.6K Buy
+168
New +$22.8K ﹤0.01% 1079
2025
Q2 		– Sell
-193
Closed -$21.3K – 1321
2025
Q1 		$21.3K Hold
193
– – ﹤0.01% 1083
2024
Q4 		$26.3K Hold
193
– – ﹤0.01% 1015
2024
Q3 		$22.2K Sell
193
-39
-17% -$5.35K ﹤0.01% 1043
2024
Q2 		$31.9K Buy
232
+34
+17% +$4.66K ﹤0.01% 1131
2024
Q1 		$26K Buy
+198
New +$27K ﹤0.01% 999

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mather Group's NBIX Position: Q2 2026 in Review

Mather Group held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 158 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1266.

Mather Group first reported a position in NBIX in Q1 2024 and has held it in 8 quarters since. The position peaked at $31.9K in Q2 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Mather Group held 158 shares of Neurocrine Biosciences worth $26.6K as of Q2 2026.
  • Mather Group left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1266 holding.
  • Mather Group first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 8 quarters since.
  • Mather Group's Neurocrine Biosciences position peaked at $31.9K in Q2 2024.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.